From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 40s
TL;DR: ALX Oncology Q3 2026 Results
ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance.
ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025. ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance. ALX Oncology Holdings Inc. reported a narrower loss for the third quarter of 2026.
- Q3 2026 Financial Results
- Net Loss Details
- Improvement from Previous Year
Read the story version — the same reporting as a swipeable deck of 3 cards.






